121 Aufrufe 121 0 Kommentare 0 Kommentare

    Aptose Announces Results from Annual and Special Meeting of Shareholders

    SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting.

    The Company is pleased to announce that all of the nominees listed in the proxy statement dated May 14, 2024, were re-elected as Directors. The results of the vote are provided below:

    Nominee Votes
    Ms. Carol G. Ashe 4,959,150
    Dr. Denis Burger 4,950,365
    Dr. Erich Platzer 4,963,215
    Dr. William G. Rice 4,331,196
    Dr. Bernd Seizinger 4,962,815
    Dr. Mark D. Vincent 4,963,303
    Mr. Warren Whitehead 4,951,313
       

    Aptose shareholders also voted in favor of the following matters:

    • the re-appointment of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024
    • an advisory (non-binding) resolution on the compensation of the Corporation’s named executive officers, as more particularly described in the Proxy Statement
    • the potential issuance of common shares of the Corporation to the holders of certain warrants in excess of 19.99% of our outstanding Shares pursuant to the Nasdaq Listing Rules
    • a resolution, the full text of which is set forth in the Proxy Statement, approving one or more adjournments of the Meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the Meeting to approve Proposal No. 4

    Please refer to the Company’s proxy statement available on SEDAR+ at www.sedarplus.ca or EDGAR https://www.sec.gov/edgar.shtml for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Aptose Announces Results from Annual and Special Meeting of Shareholders SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat …